article thumbnail

Overcoming Cost Barriers in Specialty Medication

assurecare

In the realm of Specialty Pharmacy , achieving coverage for these prescriptions by insurance after the first attempt is a rarity. Achieving coverage at a cost manageable for the average patient requires a collaborative effort from pharmacists, pharmacy technicians, nurses, patient care coordinators, and other support staff.

article thumbnail

Navigating Rilonacept Therapy: Dose Adjustments, Discontinuation, and Patient Support Strategies

Pharmacy Times

Rilonacept therapy management involves carefully evaluating patient disease stability, flare risks, and potential for discontinuation through a shared decision-making process. In an interview with Pharmacy Times ®, Allan L. We on our own help to navigate patients through that process as well.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

NHC Comments on Medicare Advantage and Prescription Drug Programs: Part C and Part D Medicare Prescription Payment Plan Model Documents

Putting Patients First Blog

Communication and Transparency Clear Communication : We emphasize the need for documents to clearly and effectively communicate the nuances of the MPPP to beneficiaries, aiding in their decision-making process.

article thumbnail

Pharmacists Have a Crucial Role Helping Patients With ATTR-CM Navigate Treatment With Tafamidis

Pharmacy Times

SHOW MORE Pharmacists can help oversee the treatment process to ensure patients with transthyretin amyloid cardiomyopathy (ATTR-CM) are adhering to tafamidis. Additionally, pharmacists are also vital in identifying financial assistance programs or navigating specialty pharmacies or mail-order services.

article thumbnail

Pharmacy Policy Updates for June 2025

Pharmacy Times

The first one was introduced on September 13, 2020, near the end of Trump’s first term, but was shut down by a federal judge due to the administration’s failure to comply with the proper implementation processes. Second, it does not address the core issues of higher prices, such as the use of rebates by insurers.